27 completed, 8 unknown, 5 terminated, 1 recruiting. 12 Phase 2, 7 Not applicable, 5 Phase 3, 4 Phase 4, 2 Early Phase 1.
Follow Blepharospasm: new trials by email Literature Review of Blepharospasm trials Research Report on Blepharospasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DaxibotulinumtoxinA for Blepharospasm Botulinum Neurotoxin Type A - Blepharospasm of Both Eyelids, Blepharospasm of Left Eyelid | Phase 2 | Recruiting | University of Pennsylvania | 20 | 2026-09-24 | 2026-09-29 |
| Safety and Efficacy of Pluripotent Stem Cell-derived Mesenchymal Stem Cell Exosome (PSC-MSC-Exo) Eye Drops Treatment for Dry Eye Diseases Post Refractive Surgery and Associated With Blepharospasm Pluripotent Stem Cell-derived Mesenchymal Stem Cell Exosome (PSC-MSC-Exo) Eye Drops - Dry Eye Disease | Phase 1 / Phase 2 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 12 | 2023-03-01 | 2023-02-22 |
| Effect of Topical Botulinum Toxin Eyedrop on Palpebral Fissure Botulinum toxin - Tears; Excess, Eyelid Spasm | Phase 4 | Terminated | University of Miami | 2 | 2022-11-29 | 2024-12-05 |
| Efficacy and Safety of 10-Week or Shorter vs 12-Week or Longer Injection Intervals of Botulinum Toxin Cervical Dystonia, Blepharospasm | Completed | University of Texas Southwestern Medical Center | 105 | 2021-11-04 | 2022-06-30 | |
| Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm Dipraglurant, Placebo - Blepharospasm, Dystonia | Phase 2 | Completed | Addex Pharma S.A. | 15 | 2021-10-06 | 2025-10-03 |
| Botulinum Toxin Relieves Anxiety, Depression and Sleep Disorderes in Patients With Blepharospasm Botulinum toxin type A - Blepharospasm | Early Phase 1 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 50 | 2021-07-12 | 2022-07-19 |
| Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm Cannabidiol Oral Solution [Epidiolex] - Blepharospasm, Blepharospasm, Benign Essential | Phase 2 / Phase 3 | Completed | Silkiss Eye Surgery | 12 | 2020-05-20 | 2021-11-02 |
| A Comparative Study of GPI's DBS and Pallidotomy in the Treatment of Meige Syndrome pallidotomy, deep brain stimulation - Meige Syndrome, Meigs Syndrome | Unknown | Peking University People's Hospital | 100 | 2020-01-01 | 2020-11-06 | |
| Analysis of Gait Before and After Botulinum Toxin Treatment in Patients With Focal Dystonia Treadmill, Botulinum Toxin injection, Severity scale of the disease - Cervical Dystonia, Primary, Blepharospasm | Not applicable | Completed | University Hospital, Grenoble | 40 | 2019-10-23 | 2025-12-22 |
| Wumeiwan Jiawei Fang Use in Patients With Blepharospasm Wumeiwan Jiawei Fang, botulinum toxin A - Dry Eye Syndromes, Meige Syndrome | Phase 2 / Phase 3 | Unknown | China Academy of Chinese Medical Sciences | 80 | 2018-01-12 | 2022-11-17 |
| Photic Blink Reflex in People With Blepharospasm and Increased Blinking Blepharospasm | Terminated | National Institute of Neurological Disorders and Stroke (NINDS) | 17 | 2017-10-30 | 2019-04-26 | |
| HLA Screening in Reducing the Risk of Antiepileptic Drug-induced Cutaneous Adverse Reactions HLA screening before commencing aromatic AEDs - Epilepsy, Neuropathy | Not applicable | Unknown | Second Affiliated Hospital of Guangzhou Medical University | 4000 | 2017-08-01 | 2018-09-05 |
| Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm Clostridium Botulinum Toxin Type A - Blepharospasm | Phase 2 / Phase 3 | Completed | Daewoong Pharmaceutical Co. LTD. | 234 | 2016-10-01 | 2019-06-26 |
| Blepharospasm Tools No intervention. - Blepharospasm, Dystonia | Completed | Emory University | 405 | 2016-08-01 | 2019-05-31 | |
| Two Different Surgical Methods of Blepharospasm Facial nerve combing, Facial and Trigeminal nerve combing - Blepharospasm | Early Phase 1 | Unknown | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 40 | 2016-05-01 | 2016-05-06 |
| A Retrospective Chart Review of BOTOX® and Xeomin® for the Management of Cervical Dystonia and Blepharospasm No Intervention - Cervical Dystonia, Blepharospasm | Completed | Allergan | 44 | 2015-08-01 | 2016-01-08 | |
| An RCT of a Patient-initiated Treatment Service for BEB and HFS Patient-initiated treatment - Blepharospasm, Hemi Facial Spasm | Not applicable | Completed | Moorfields Eye Hospital NHS Foundation Trust | 130 | 2015-08-01 | 2022-04-12 |
| Pretarsal Versus Preseptal Botulinum Toxin for Patients With Eyelid Spasm Botulinum Toxin Type A 100Unit/Vial (Product), Saline Solution for Injection - Blepharospasm, Hemifacial Spasm | Phase 4 | Completed | The University of Hong Kong | 100 | 2015-07-01 | 2019-04-26 |
| Comparison of Different Botulinum Toxin A Injection Patterns in the Treatment of Blepharospasm Botulinum toxin A injection (5 sites: 12.5U), Botulinum toxin A injection (4 sites: 10U), Botulinum toxin A 12.5U - Blepharospasm | Not applicable | Unknown | YangHui | 120 | 2013-02-01 | 2014-12-30 |
| A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm No Intervention - Cervical Dystonia, Blepharospasm | Completed | Allergan | 48 | 2013-01-01 | 2014-07-03 |
Showing 20 of 41. Sign in to see all of them.
Dystonia (14) · Torticollis (10) · Dystonic Disorders (6) · Hemifacial Spasm (5) · Muscle Spasticity (3) · Benign essential blepharospasm (2) · Dry Eye Syndromes (2) · Lacerations (2) · Meige Syndrome (2) · Spasm (2) · Blepharoptosis (1) · Cerebellar Diseases (1) · Cerebral Palsy (1) · Cervical Dystonia, Primary (1)
Eye Diseases (41) · Eyelid Diseases (41) · Neurologic Manifestations (23) · Pathological Conditions, Signs and Symptoms (23) · Signs and Symptoms (23) · Nervous System Diseases (21) · Dyskinesias (20) · Central Nervous System Diseases (12) · Movement Disorders (9) · Neuromuscular Manifestations (8) · Brain Diseases (6) · Dystonia (6) · Mouth Diseases (6) · Stomatognathic Diseases (6) · Spasm (5)
Botulinum Toxins, Type A (12) · incobotulinumtoxinA (4) · Botulinum Toxins (3) · Deep Brain Stimulation (2) · Injections (2) · 26S proteasome non-ATPase regulatory subunit 13 (1) · 6-fluoro-2-(4-(pyridin-2-yl)but-3-yn-1-yl)imidazo(1,2-a)pyridine (1) · Cannabidiol (1) · Drug Delivery Systems (1) · Exercise Test (1) · Mexiletine (1) · Ophthalmic Solutions (1) · Pallidotomy (1) · Pharmaceutical Preparations (1) · Saline Solution (1)
National Institute of Neurological Disorders and Stroke (NINDS) (8) · Allergan (4) · Merz Pharmaceuticals GmbH (3) · Ipsen (2) · Second Affiliated Hospital, Zhejiang University, School of Medicine (2) · Addex Pharma S.A. (1) · Aurolab (1) · China Academy of Chinese Medical Sciences (1) · Daewoong Pharmaceutical Co. LTD. (1) · Emory University (1) · Merz North America, Inc. (1) · Moorfields Eye Hospital NHS Foundation Trust (1) · Oxford University Hospitals NHS Trust (1) · Pacific Pharmaceuticals (1) · Peking University People's Hospital (1)
United States (19) · China (7) · Canada (4) · Germany (4) · United Kingdom (3) · France (2) · South Korea (2) · India (1) · Italy (1) · Mexico (1) · Norway (1) · Russia (1)
Mark Hallett, M.D. (2) · Bettina Wabbels, MD (1) · Codrin I Lungu, M.D. (1) · Daniel Ezra, MD FRCOph (1) · H. A. Jinnah, MD, PhD (1) · Hubert H. Fernandez, MD, FAAN (1) · Hui Yang, MD, PhD (1) · Huina Zhang (1) · Jiajun Xie (1) · Jill Ostrem, M.D. (1) · John Harvey, MD (1) · John S Elston, MD FRCS OPTH (1)
PMID 19794937, PMID 21520284, PMID 23435927, PMID 26885381, PMID 27903810, PMID 35300599, PMID 37606606, PMID 38310362, PMID 38386480, PMID 39839752
U54TR001456 (1)